Clinical trials: Differentiation
Cancer, Thyroid Carcinoma
Thyroid Cancer and Sunitinib
Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this…
- Trial name
- THYSU (NCT00510640)
- Testing
- Sunitinib
- Where
- 15 sites in France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Bordeaux
Low Risk Differentiated Thyroid Cancer
Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid…
- Trial name
- NCT05510934
- Testing
- Shared-care model
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Nova Scotia Health Authority
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00054236
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Case Comprehensive Cancer Center
Biomarkers in Seizures
Inflammatory Biomarkers in Seizure
1. Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure. 2. Possible role to predict the prognosis of patients with epileptic seizure
- Trial name
- seizure (NCT05556109)
- Testing
- Inflammatory serum biomarkers
- Volunteers
- 90 people
- Sponsor
- Assiut University
CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy…
- Trial name
- NCT01933711
- Testing
- rituximab
- Where
- 3 sites in Germany
- Volunteers
- 328 people
- Sponsor
- University Hospital Heidelberg
Thyroid Cancer
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong…
- Trial name
- NCT06860971
- Testing
- AL2846 Capsules
- Where
- 35 sites in China
- Volunteers
- 144 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neuroendocrine Tumors
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium[177Lu] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with…
- Trial name
- NCT05459844
- Testing
- Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR
- Where
- 23 sites in China
- Volunteers
- 196 people
- Sponsor
- Sinotau Pharmaceutical Group
Postoperative Chemotherapy, Chemotherapy
Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy
4.1 Research Content 1. Clarifying the acupoint application scheme for deficiency and constipation in CRC patients undergoing chemotherapy: the preliminary acupoint application scheme for deficiency and constipation in CRC…
- Trial name
- NCT07276932
- Testing
- Acupoint application, Routine treatment and nursing of constipation
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Leukemia, Neutropenia
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002658
- Testing
- filgrastim, amsacrine, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Medical Research Council
Thyroid Cancer
Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers
This is a multicenter randomized controlled trial including patients with small (<2 cm) suspected or confirmed thyroid cancers. Patients are included after informed consent and randomized to one of two treatments.
- Trial name
- NCT06796348
- Testing
- Radiofrequency ablation alone, Surgery
- Where
- Denmark
- Volunteers
- 88 people
- Sponsor
- University of Aarhus
Heart Arrest, Out-Of-Hospital, Computed Tomography
Head Computed Tomography for Predicting Neurological Outcome After Cardiac Arrest
The European Resuscitation Council (ERC) and the European Society of Intensive Care Medicine (ESICM) joint guidelines for post-resuscitation care recommend a multimodal approach to prognostication of neurological outcome.
- Conditions
- Heart Arrest, Out-Of-Hospital, Computed Tomography, Unconsciousness, Neurologic Deficits
- Trial name
- NCT03913065
- Testing
- CT
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Lund University
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Pancreatic Cancer
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin (strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy regimens in the treatment of well…
- Trial name
- BETTER2 (NCT03351296)
- Testing
- LV5FU2, Streptozocin, Capecitabine
- Where
- 20 sites in France
- Volunteers
- 140 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned (recurrent) or has spread from where it started to other places in the body…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT02393690
- Testing
- Iodine I-131, Selumetinib
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Academic and Community Cancer Research United
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
- Trial name
- NCT01845675
- Testing
- temozolomide or dacarbazine-based chemotherapy, endostatin
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Peking Union Medical College Hospital
Thyroid Neoplasms
Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma
Human thyroglobulin (Tg) is the most sensitive biochemical marker for recurrence of differentiated cancer (DTC), especially after the complete removal of thyroid tissue through surgery and radioiodine therapy (RIT).
- Trial name
- NCT00148213
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Muenster
Type 1 Diabetes Mellitus
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
- Trial name
- PROTECT (NCT03875729)
- Testing
- teplizumab
- Where
- 62 sites in United States, Belgium and 7 more
- Volunteers
- 328 people
- Sponsor
- Provention Bio, Inc.
Differentiated Thyroid Cancer
Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients
Background: Despite the good prognosis of patients with differentiated thyroid carcinomas (DTC), the diagnosis of cancer, fear of cancer recurrence and its side effects might still bring impacts on patients' quality of life and…
- Trial name
- NCT03757637
- Testing
- NLSCP, ICT supported HAP
- Where
- Taiwan
- Volunteers
- 380 people
- Sponsor
- National Taiwan University Hospital
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05286801
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Carcinomas
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and digestive.
- Trial name
- BEVANEC (NCT02820857)
- Testing
- Folfiri-bevacizumab, Folfiri
- Where
- 26 sites in France
- Volunteers
- 153 people
- Sponsor
- Hospices Civils de Lyon